Publications by authors named "Yuanyang Xiao"

2 Publications

  • Page 1 of 1

Antiproliferative effects of Norartocarpetin isoflavone in human lung carcinoma cells are mediated via targeting Ras/Raf/MAPK signalling pathway, mitochondrial mediated apoptosis, S-phase cell cycle arrest and suppression of cell migration and invasion.

J BUON 2020 Mar-Apr;25(2):855-861

Department of Cardio Thoracic Surgery, Puren Hospital of Wuhan University of Science and Technology, Wuhan 430081, China.

Purpose: The main purpose of the current research work was to investigate the anticancer activity of norartocarpetin - a plant derived isoflavone -in human lung carcinoma cells NCI-H460 and normal lung cell line MRC-9 along with studying its effects on cellular apoptosis, DNA damage, cell migration and invasion and Ras/Raf/MAPK signalling pathways.

Methods: Cell proliferation was examined by CCK-8 assay while effects on apoptosis were evaluated by acridine orange (AO)/ethidium bormide (EB) staining and Comet assay using fluorescence microscopy. In vitro wound healing assay was used for checking the effects on cell migration and transwell assay for invasion while western blot was used to evaluate the effects on the expression of Ras/Raf/MAPK proteins.

Results: The results showed that Norartocarpetin led to dose-dependent cytotoxic effects in NCI-H460 cells showing an IC50 value of 22 μM while in normal lung cells, the cytotoxic effects were much lower as shown by higher IC50 value of 85 μM. It also led to dose-dependent apoptosis and induced DNA damage as shown by fluorescence microscopy. This molecule also inhibited cell migration and invasion dose-dependently, along with inhibiting MMP-9 expression. Norartocarpetin treatment also led to inhibition of the expression of Ras/Raf/MAPK proteins and also caused S-phase cell cycle arrest in these cells.

Conclusion: Norartocarpetin has a significant anticancer activity in lung carcinoma cells and these effects are mediated via targeting apoptosis, DNA damage, cell migration and invasion, cell cycle and inhibiting Ras/Raf/MAPK signalling pathways.
View Article and Find Full Text PDF

Download full-text PDF

Source
February 2021

[Retrospective study on incomplete intestinal obstruction treated with the adjuvant therapy of acupuncture and moxibustion].

Zhongguo Zhen Jiu 2018 Jul;38(7):707-10

General Surgery Department, Beijing Royal Integrative Medicine Hospital, Beijing 102209, China.

Objective: To evaluate the clinical effects on incomplete intestinal obstruction treated with the adjuvant therapy of acupuncture and moxibustion.

Methods: Using the retrospective analysis, 80 patients of incomplete intestinal obstruction were divided into an observation group and a control group, 40 cases in each one. In the control group, the routine treatment was given, such as fasting, gastrointestinal decompression, parenteral nutrition, infection prevention with antibiotics and enema laxative. In the observation group, on the basis of the treatment as the control group, acupuncture was applied at bilateral Zusanli (ST 36), Shangjuxu (ST 37) and Xiajuxu (ST 39); moxibustion was used at left Yangchi (TE 4), Zhongwan (CV 12), Qihai (CV 6) and Guanyuan (CV 4). The treatment was given once a day, 30 min each time. The average days of treatment, the surgical transfer rate, the time to first flatus, the recovery time of defecation and the time of solid food intake were observed in the patients of the two groups.

Results: The average days of treatment in the observation group was obviously less than that in the control group (<0.05). The surgical transfer rate in the observation group was obviously lower than that in the control group (<0.05). The time to first flatus, the recovery time of defecation and the time of solid food intake were all obviously earlier than those in the control group (all <0.05).

Conclusion: The adjuvant therapy of acupuncture and moxibustion achieves the significant therapeutic effects on incomplete intestinal obstruction, shortens the treatment duration and reduces the surgical transfer rate and the patient's economic burden.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.13703/j.0255-2930.2018.07.006DOI Listing
July 2018
-->